SMARCB1 (INI-1) is a tumor-suppressor gene located on chromosome 22q11.2. Its gene product is ubiquitously expressed in nuclei of all normal tissues. SMARCB1 gene inactivation has been implicated in the pathogenesis of a diverse group of malignant neoplasms that tend to share "rhabdoid" cytomorphology. This group of SMARCB1-deficient tumors is now further expanded by a subset of carcinomas arising in the sinonasal tract. SMARCB1 immunostaining was performed on 142 sinonasal carcinomas. Tumors that showed loss of expression were further characterized for SMARCB1 deletions by fluorescence in situ hybridization. Nine of 142 (6%) primary sinonasal carcinomas showed loss of SMARCB1 expression by immunohistochemistry. Five patients were women, and patients ranged in age from 33 to 78 years (mean 59 y). The SMARCB1deficient tumors were characterized by nests, sheets, and cords of cells without any histologic evidence of specific (eg, squamous or glandular) differentiation. The tumors comprised varying proportions of basaloid and rhabdoid cells. The SMARCB1deficient carcinomas had been diagnosed as nonkeratinizing squamous cell carcinomas (n = 3), sinonasal undifferentiated carcinomas (n = 2), myoepithelial carcinoma (n = 2), nonintestinal adenocarcinoma (n = 1), and carcinoma, not otherwise specified (n = 1). Fluorescence in situ hybridization analysis revealed SMARCB1 deletions in 6 of 8 (75%) carcinomas. The SMARCB1-deficient carcinomas did not harbor human papillomavirus or NUT-1 alterations. Six patients presented with T4 disease, 5 patients developed local recurrences and/or distant metastases, and 4 died of their disease. Inactivation of the SMARCB1 tumor-suppressor gene appears to be involved in the pathogenesis of a subset of sinonasal carcinomas, further expanding the family of SMARCB1-deficient neoplasms and further delineating a bewildering group of poorly/undifferentiated, aggressive carcinomas arising at this site. The ability to detect SMARCB1 loss by immuno-histochemistry, particularly when dealing with poorly differentiated carcinomas with basaloid or rhabdoid features, should facilitate a more comprehensive understanding of these sinonasal carcinomas including clinical behavior and response to targeted therapies.
C arcinomas of the sinonasal tract account for 3% of those malignant neoplasms occurring in the head and neck, 1 and they afflict 0.5 to 1.0 patient per 100,000 per year. 2, 3 Although some of these are squamous cell carcinomas, the sinonasal tract is a site where highly aggressive and poorly differentiated carcinomas that defy straightforward histologic subclassification are often encountered. The mechanisms underlying the development of sinonasal cancer are also elusive. Exposure to occupational carcinogens (eg, wood dust, formaldehyde) has been implicated in only a small subset of sinonasal carcinomas, and the link between cigarette smoking and cancer development is much weaker compared with other head and neck sites, suggesting alternative genetic mechanisms and distinct genetic targets. [4] [5] [6] As these non-tobacco-related mechanisms of head and neck tumorigenesis become better defined, the group of poorly/undifferentiated carcinomas may turn out to represent a heterogenous mix of tumors defined by distinct pathogenic mechanisms. Recent studies, for example, have shown that 20% to 25% of nonkeratinizing sinonasal cancers are caused by oncogenic human papillomavirus (HPV) 7-10 ; a subset of tumors previously regarded as poorly differentiated squamous cell carcinoma or sinonasal undifferentiated carcinoma has been found to harbor activating translocations involving the NUT gene (ie, NUT midline carcinomas). [11] [12] [13] Despite these recent developments, the underlying mechanisms for most sinonasal carcinomas remain unknown. SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1, also known as INI-1 or SNF5) is a tumor-suppressor gene located on chromosome 22q11.2. 14 Its gene product is a member of the SWI/SNF chromatin-remodeling complex that regulates transcription, and it is ubiquitously expressed in the nuclei of all normal tissues at levels that can be readily detected by routine immunohistochemistry. [14] [15] [16] [17] [18] Deficiency of SMARCB1 was first recognized as a distinguishing feature of atypical teratoid/rhabdoid tumor of the central nervous system and malignant rhabdoid tumors of the kidney and soft tissue. [19] [20] [21] [22] [23] [24] [25] Since then, the list of SMARCB1-deficient tumors has grown to include epithelioid sarcoma, [26] [27] [28] renal medullary carcinoma, 29 myoepithelial carcinoma of soft tissue, 26, 30 epithelioid malignant peripheral nerve sheath tumor, 26 and extraskeletal myxoid chondrosarcoma. 31 Although these diverse tumor types differ in many respects, they all tend to include the presence of "rhabdoid" cells, defined as large cells with abundant eosinophilic cytoplasm and eccentrically placed nuclei with open chromatin and prominent nucleoli. Ultrastructurally, cytoplasmic eosinophilia reflects the accumulation of compact whorls of intermediate filaments. Although the list of anatomic sites is growing, the sinonasal tract has not yet been identified as a site of SMARCB1deficient tumors.
METHODS

Cases/Tissue Microarray
A tissue microarray was constructed from the paraffin-embedded tissue blocks of 140 consecutive primary sinonasal carcinomas of all histologic types, as previously described. 7 The tumors included on the tissue microarray consisted of 81 squamous cell carcinomas and variants (including 40 nonkeratinizing forms), 34 salivary-type adenocarcinomas, 14 sinonasal undifferentiated carcinomas, 6 nonsalivary-type adenocarcinomas, 3 NUT midline carcinomas, and 2 small cell carcinomas. Three cores, each 1 mm in diameter, were taken from each donor block to address tumor heterogeneity. Two additional cases from the authors' (W.H.W. and J.A.B.) consultation practice were selected for SMARCB1 testing on the basis of morphologic similarity to SMARCB1-deficient tumors identified from the tissue microarray. Pertinent clinical information was obtained from The Johns Hopkins Hospital's electronic medical records.
Immunohistochemistry
All 142 sinonasal cancers were evaluated by immunohistochemistry for SMARCB1 (BAF47; BD Biosciences, San Diego, CA) on 5-mm-thick sections on a Leica Bond-III autostainer (Leica Biosystems, Buffalo Grove, IL). Normal tonsil served as positive control tissue, whereas an epithelioid sarcoma served as an SMARCB1-deficient tumor control. For cases that demonstrated loss of SMARCB1 immunoexpression on TMA, additional immunohistochemical staining analyses were performed on full sections using the Ventana Benchmark XT autostainer (Ventana Medical Systems Inc., Tucson, AZ). Antigen retrieval was completed using a high pH buffer, followed by primary antibody incubation for 32 minutes. The samples were then stained using a Ventana BenchMark ULTRA automated stainer and an ultraView detection system according to manufacturer's instructions (Ventana). The primary antibodies and final dilutions of the extended immunohistochemical panel were: p63 (clone 4A4; Cell Marque Corp., Rocklin, CA; prediluted by manufacturer); p40 (Ab-1; Oncogene Research Products, Cambridge, MA; 1:2000 dilution); muscle-specific actin (clone HHF35; Ventana); calponin (clone CALP; Dako, Carpinteria, CA); S100 protein (clone 4C4.9; Ventana; prediluted); synaptophysin (clone 27G12; Leica; prediluted), chromogranin (clone LK2H10; Ventana; prediluted); and AE1/AE3 (clone PCK26; Ventana; prediluted). Finally, mucicarmine histochemical staining was done on all SMARCB1-deficient cases, adhering to the methods described in the AFIP Laboratory Methods in Histotechnology. 32 NUT-1 (C52B1, Cell Signaling Technologies Inc., Danvers, MA) and p16 (clone INK4a; MTM Laboratories, Heidelberg, Germany; prediluted) immunohistochemical analysis and DNA in situ hybridization for HPV were carried out and reported as previously detailed. 7, 11 The in situ hybridization testing utilized both type-specific assays for types 16 
SMARCB1 and EWSR1 Fluorescence In Situ Hybridization
All SMARCB1-deficient tumors were then tested by fluorescence in situ hybridization (FISH) for the presence of SMARCB1 gene abnormalities. Subsequently, cases that were SMARCB1 negative by immunohistochemistry but lacked SMARCB1 gene alterations were further tested by FISH for potential rearrangements in EWSR1; the latter were previously reported in a subset of SMARCB1-deficient myoepithelial carcinomas of soft tissue. 28 FISH was performed using custom BAC probes as previously described. 28 Copy number abnormalities were assessed on 100 nuclei. A normal copy number pattern was defined when 2 copies of the SMARCB1 gene or other members of the SWI/SNF complex were identified, with a 1:1 ratio to the control probe (ie, telomeric-EWSR1 or 22q11). Heterozygous deletion was defined as only 1 copy of the gene of interest being present compared with the reference control probe on 22q (ratio 2:1). Homozygous deletion of SMARCB1 was interpreted when both copies of the gene were lost, compared with the control probes, either telomeric-EWSR1 or 22q11.
RESULTS
SMARCB1 Immunohistochemical Staining
Seven (5%) of the 140 consecutive primary sinonasal carcinomas studied on the tissue microarray demonstrated complete loss of SMARCB1 immunohistochemical expression. On the basis of the morphologic appearance of these SMARCB1-deficient carcinomas (see below), 2 additional consultation cases were also tested for SMARCB1 immunohistochemistry, and both were negative for SMARCB1 expression. Thus a total of 9 SMARCB1deficient sinonasal carcinomas were included in the study. In all these 9 cases, strong nuclear SMARCB1 staining was present in the surrounding non-neoplastic tissues ( Fig. 1 ).
Morphologic Findings
Histologic examination of the SMARCB1-deficient sinonasal carcinomas revealed tumors that typically grew as rounded and anastamosing nests of tumor cells separated by bands of fibrous stroma. In areas, some of the tumors became more sheet-like or cord-like in architecture. A single case demonstrated a spindled (ie, sarcomatoid) component. The carcinomas tended to be highly infiltrative with frequent bone invasion. The tumor nests comprised cells that had enlarged round nuclei with prominent nucleoli, but their cytoplasmic qualities varied. In cases in which the tumor cells had scant cytoplasm, they were basaloid in morphology; but all of the tumors harbored at least a subset cells with abundant, eccentric, eosinophilic cytoplasm imparting a rhabdoid appearance. The rhabdoid cells were often scattered singly among the more basaloid cells ( Fig. 2A ), but in some cases they were the predominant cell type ( Fig. 2B ). Tumor necrosis was a frequent finding, and the mitotic rate was high (ranging from 3 to 30 mitoses per 10 high-power fields, mean 12). Despite these aggressive histologic features, the carcinomas lacked significant pleomorphism at the cellular level. None of the carcinomas showed overt evidence of squamous or glandular differentiation by routine histology. There was no evidence of dysplasia or carcinoma in situ in the overlying surface epithelium. Five of the carcinomas demonstrated duct-like spaces that were sometimes associated with necrotic tumor cells and appeared to represent pseudoglandular spaces. Intracellular mucin was detected in 2 cases (22%), but its presence was a very focal finding.
Immunohistochemistry
The immunohistochemical findings are summarized in Table 1 . All 9 SMARCB1-deficient carcinomas were positive for AE1/AE3, 4 of 9 (44%) showed nuclear labeling for p63 and p40, which was either diffuse (n = 3) or focal (n = 1); 5 of 8 (63%) were focally positive for synaptophysin (staining not done on 1 case because of insufficient tissue), and 1 (11%) showed focal S100 protein staining. All tumors were negative for actin, chromogranin, and NUT-1. Two (33%) cases were diffusely positive for p16, but high-risk HPV was not detected in any of the carcinomas by DNA in situ hybridization.
Original Tumor Classification
The original diagnostic classification of these SMARCB1-deficient carcinomas, as based on the mor-phologic and immunohistochemical features, is shown in Table 1 . Three of the carcinomas were originally diagnosed as nonkeratinizing squamous cell carcinomas, largely on the basis of the presence of diffuse p63 staining. In the absence of any squamous, glandular, or other specific differentiation, 2 of the carcinomas were classified as sinonasal undifferentiated carcinomas. One case was originally regarded as a high-grade nonintestinal adenocarcinoma on the basis of pseudoglandular spaces and focal mucicarmine staining. Despite negative immunostaining for p63, S100, and actin, 2 of the tumors were originally regarded as myoepithelial carcinoma. These 2 tumors were lower grade than the others and had an appearance that was originally interpreted as plasmacytoid rather than rhabdoid ( Fig. 3) . Overall, the SMARCB1-deficient carcinomas represented 3 of 40 (8%) tumors that had been regarded as nonkeratinizing squamous cell carcinomas, 2 of 14 (14%) sinonasal undifferentiated carcinomas, 2 of the 34 (9%) of tumors that were regarded as salivary in origin (including 2 of the 3 originally classified as myoepithelial carcinoma), and 1 of 6 (17%) nonsalivary adenocarcinomas.
SMARCB1 Fluorescence In Situ Hybridization
FISH for the presence of SMARCB1 gene abnormalities was successfully performed in 8 of 9 cases on full sections. One case failed due to decalcification of the only available tumor block. Six of 8 (75%) of the SMARCB1deficient carcinomas showed SMARCB1 copy number alterations. Five cases showed homozygous deletion of SMARCB1 (Fig. 4A) , whereas an additional case showed a heterozygous deletion pattern (Fig. 4B) . Interestingly, the 2 SMARCB1-deficient carcinomas lacking SMARCB1 gene abnormalities by FISH were associated with a lower histologic grade and were originally felt to represent myoepithelial carcinoma. Because rare SMARCB1-deficient myoepithelial tumors of soft tissue harbor EWSR1 gene Am J Surg Pathol Volume 38, Number 9, September 2014 SMARCB1 (INI-1)-deficient Carcinomas of Sinonasal Tract rearrangements, 28 these 2 carcinomas were also tested for EWSR1 FISH, but no gene abnormalities were noted.
Clinical Findings
The clinical characteristics of the patients with SMARCB1-deficient sinonasal carcinomas are summarized in Table 2 . Five of patients with SMARCB1-deficient sinonasal carcinomas were female, and 4 were male. The patients ranged in age from 33 to 78 years (mean 59 y). Three patients (33%) had histories of smoking, and 1 patient (11%) also had a history of alcohol abuse. The presenting symptoms included pain (n = 5), eye symptoms (eg, blurry vision, tearing) (n = 4), and nasal obstruction (n = 2). The carcinomas involved the paranasal sinuses (n = 9), orbit (n = 5), nasal cavity (n = 4), brain (n = 3), and skull base (n = 2) (Fig. 5 ). The affected paranasal sinuses were: ethmoid (n = 8), maxillary (n = 3), and frontal (n = 2). The tumor sizes were known in 8 cases; they ranged from 2.5 to 9 cm (mean, 4.9 cm). At the time of presentation, none of the patients had regional or distant metastases. The tumor stages were T2 N0 M0 (n = 1), T3 N0 M0 (n = 2), and T4 N0 M0 (n = 6). CT indicates chemotherapy; DM, distant metastases; DWD, died with disease; F, female; LR, local recurrence; M, male; NA, not applicable; NED, no evidence of disease; RM, regional metastases; RT, radiation therapy.
All patients with SMARCB1-deficient sinonasal carcinoma underwent surgical resection of their tumors. One patient received surgical management alone, whereas 4 patients received surgery and radiotherapy, and 3 patients received surgery with combined chemoradiation. In addition, 1 patient received surgery and has radiotherapy planned, but it has not yet started. The available follow-up ranged from 0 to 57 months (median, 16 mo). For 1 patient, no follow-up information was available because the patient's treatment is not complete. Four patients experienced local recurrences at 7, 9, 11, and 12 months after treatment; 1 of these patients also had regional lymph node metastases. All 4 patients were then treated with chemotherapy; 1 patient with local recurrence and regional metastasis also underwent additional surgery (local reexcision and neck dissection). Two patients experienced distant metastases, at 13 and 17 months, respectively. These distant metastases were present in the brain (n = 2), bone (n = 1), lung (n = 1), and scalp (n = 1). Unfortunately, 4 of the 8 patients with follow-up information died of their disease, at 15, 15, 29, and 30 months after treatment. These patients included 3 of the 6 tumors found to have SMARCB1 deletions and 1 of the 2 tumors without SMARCB1 deletion. The remaining 4 are alive with no evidence of disease at 10, 16, 26, and 57 months after treatment.
DISCUSSION
Using immunohistochemistry to screen a large and diverse group of sinonasal carcinomas for loss of SMARCB1 expression, we found that 5% exhibited complete loss of staining. The genetic basis for loss of protein expression was confirmed in most of these cases: 6 of the 8 tumors demonstrating homozygous (n = 5) or heterozygous (n = 1) deletions of the SMARCB1 tumorsuppressor gene by FISH. The lack of SMARCB1 deletions in 2 cases points to alternative inactivating events below the FISH resolution such as intragenic mutations, small deletions, or epigenetic silencing. In addition, 1 SMARCB1-deficient myoepithelial carcinoma of soft tissue has been previously reported to harbor an EWSR1 gene rearrangement without SMARCB1 gene abnormalities by FISH, 28 although this mechanism was not confirmed in our 2 SMARCB1-deficient tumors that had been originally diagnosed as myoepithelial carcinomas. SMARCB1 loss was not randomly distributed across all types of sinonasal carcinomas, but tracked with tumors demonstrating rhabdoid features-a cytomorphologic trait shared by SMARCB1-deficient tumors across diverse anatomic sites. The degree of rhabdoid differentiation was highly variable and ranged from rhabdoid cells singly dispersed among basaloid cells to confluent sheets of polygonal cells with a more plasmacytoid appearance. Recognition of these rhabdoid features was useful in identifying 2 additional SMARCB1-deficient sinonasal carcinomas that were sent for second opinion consultation. Conversely, failure to appreciate these rhabdoid features can cause confusion with other poorly/undifferentiated carcinomas of the sinonasal FIGURE 5 . Most of the SMARCB1-deficient sinonasal carcinomas exhibited aggressive clinical behavior. This tumor extended from the right sinonasal tract to involve the orbit and brain (T2-weighted magnetic resonance imaging).
Am J Surg Pathol Volume 38, Number 9, September 2014 SMARCB1 (INI-1)-deficient Carcinomas of Sinonasal Tract tract. Although SMARCB1-deficient carcinomas represent only a small subset of primary sinonasal carcinomas overall, they accounted for 14% of those tumors that had been originally diagnosed as sinonasal undifferentiated carcinoma. Just as with the recent discovery of NUT-1 gene activation in some undifferentiated sinonasal carcinomas, and the detection of integrated high-risk HPV in some basaloid sinonasal carcinomas, identification of SMARCB1 deficiency could help redefine the classification in a more precise and relevant way. Secondary SMARCB1 loss in a conventional tumor type resulting in a composite rhabdoid tumor is a wellrecognized phenomenon. The rhabdoid phenotype has been encountered as a separate and distinct constituent within conventional parent tumors showing carcinomatous, sarcomatous, melanocytic, glial, meningothelial, and other lines of differentiation. 33, 34 This phenomenon has prompted the notion that some extrarenal rhabdoid tumors do not warrant separate classification as a unique tumor type. 35, 36 In the cases we report, there was no evidence of an associated conventional differentiated carcinoma. Some were originally categorized as squamous carcinoma on the basis of diffuse immunostaining for p63, but there was no histologic evidence of squamous differentiation or surface squamous dysplasia in any of the cases. Two were originally classified as myoepithelial carcinoma largely on the basis of the myoepithelial-like plasmacytoid appearance of the tumor cells, but myoepithelial differentiation could not be confirmed by immunohistochemistry. In effect, the SMARCB1-deficient sinonasal carcinomas that we report may represent a distinct tumor type.
In other sites, the rhabdoid morphology heralds an aggressive type associated with a dismal clinical outcome. On the basis of our limited number of cases, SMARCB1deficient sinonasal carcinomas also have a tendency to behave aggressively as evidenced by advanced local stage at time of presentation, a potential for regional and distant spread, and a mortality rate of 50% with a mean survival of 22 months. The recognition of SMARCB1 loss as a driving genetic alteration now provides a rational target for the development of targeted therapies. [37] [38] [39] [40] [41] [42] [43] [44] In summary, a subset of sinonasal carcinomas harbors inactivating alterations of the SMARCB1 tumorsuppressor gene. Although these tumors are likely to be classified as nonkeratinizing squamous cell carcinomas, sinonasal undifferentiated carcinomas, and myoepithelial carcinomas, they likely represent a unique type of sinonasal carcinoma that further expands the family of SMARCB1-deficient tumors. Although the number of cases we report is limited, use of routine SMARCB1 immunohistochemistry as an easy way to recognize this entity and separate it from other poorly differentiated sinonasal carcinomas should facilitate the accrual of additional cases toward a more complete understanding of its pathologic and clinical features.
